91猫先生

Professional Experience

2026–present  Adjunct Professor of Pathology, College of Medicine, 91猫先生

2011–2029  Board Director, Supervisor, Executive Board Director, and Executive Supervisor, Taiwan Society of Pathology

2023–2026  Chair, Department of Anatomic Pathology, Kaohsiung Chang Gung Memorial Hospital

2012–present  Adjunct Professor of Pathology, College of Medicine, 91猫先生

2019–present  Editorial Board Member, Human Pathology (SCI)

2013–present  Executive Board Director, Taiwan Society of Pathology

2004–present  Consultant and Convener for Bone and Soft Tissue Pathology, Health Promotion Administration, Ministry of Health and Welfare

1999–present  Attending Pathologist, Department of Anatomic Pathology, Kaohsiung Chang Gung Memorial Hospital

2010–2017  Chair, Department of Anatomic Pathology, Kaohsiung Chang Gung Memorial Hospital

2011, 2013, and 2021  Co-convener of the 7th (Taipei, Taiwan), 8th (Busan, Korea), and 12^th (Okayama, Japan) Asia-Pacific IAP congress, bone and soft tissue session

2012–2020  Member, Molecular Pathology Education Committee, Taiwan Society of Pathology

2008–2009, 2011–2012, 2014, and 2017  Review Panel Member for Anatomy, Forensic Medicine, and Pathology, National Science and Technology Council

2009–2011  Full-time Associate Professor of Pathology, College of Medicine, 91猫先生

2006–2009  Full-time Assistant Professor of Pathology, College of Medicine, 91猫先生

2004–2006  Adjunct Assistant Professor of Pathology, Shu-Zen Junior College of Medicine and Management

2001–2003  Fellow in Bone and Soft Tissue Pathology, Memorial Sloan Kettering Cancer Center, USA

1995–1999  Resident, Department of Pathology, Kaohsiung Chang Gung Memorial Hospital

1995  Resident, Department of Neurology, Kaohsiung Medical University Hospital

Professional Memberships & Certifications

Taiwan Society of Pathology / Taiwan Division of the International Academy of Pathology

United States and Candian Academy of Pathology

International Society of Bone and Soft tissue Pathology

Research Projects (Past Three Years)

National Science and Technology Council (NSTC):

1. Oncogenic mechanisms, clinicopathologic significance, and therapeutic relevance of SHOX2 overexpression in myxofibrosarcoma through novel protein interactions: elucidating a coordinated network involving ERK activation, USP11-mediated deubiquitination, and EZH2-driven gene repression (114-2320-B-182A-010-MY3, 2025/8/1–2028/7/31)

2. Molecular mechanisms and clinicopathologic implications of the thiamine transporter SLC19A2 as a tumor suppressor in myxofibrosarcoma: novel functional roles in anti-angiogenesis, suppression of invasiveness, and mitochondria-related metabolic reprogramming (111-2320-B-182A-006-MY3, 2022/8/1–2025/7/31)

Chang Gung Research Projects

1.   Integrative transcriptomic and epigenetic analyses of differences and similarities between bona fide kinase fusions and wild-type kinase upregulation in fusion-driven sarcomas (CMRPG8Q0821)

2.   Integrated analyses of transcriptomic expression, whole-exome sequencing, and methylomics to identify molecular determinants of prognosis in solitary fibrous tumors beyond WHO-defined risk stratification (CMRPG8P0821)

3.  Transcriptomic and methylomic characterization of mesenchymal tumors resembling RB1-deficient fibrofatty tumors but harboring PLAG1/HMGA2 fusions: determining whether they represent a distinct novel tumor entity or genetic variants of existing tumor types (CMRPG8N0891)

4.   Comprehensive molecular characterization of SH3PXD2A::HTRA1 gene fusions across peripheral nerve sheath tumors: diagnostic value in a distinctive schwannoma subset, clinicopathologic correlations, and potential biological and pathogenetic implications (CMRPG8M1201, CMRPG8M1202)

Industry-Sponsored Research Projects

1.  Detection of NTRK or functionally analogous kinase fusions in spindle cell mesenchymal tumors, inflammatory myofibroblastic tumors, and cholangiocarcinomas by combining pan-TRK immunohistochemical screening with fusion kinase–focused RNA sequencing (XPRPG8P0041)

2.  Investigation of diverse potentially pathogenic aberrations in pan-TRK-positive gastrointestinal stromal tumors, with emphasis on intestinal and recurrent cases (XPRPG8N0131, XPRPG8N0132)

Selected Publications (2021–2026)

1.Wang JC, Li WS^*, Kao YC, Lee JC, Lee PH, Huang SC, Tsai JW, Chen CC, Chang CD, Yu SC, Huang HY*. Clinicopathologic and molecular characterization of USP6-rearranged soft tissue neoplasms: The evidence of genetic relatedness indicates an expanding family with variable bone-forming capacity. Histopathology. 2021 April:78.676-689  (SCI 2023 IF: 3.9, rank: 17/88 =19.3 % in Pathology, co-corresponding author)

2. Li CF, Chan TC, Wang CI, Fang FM, Lin PC, Yu SC, Huang HY*. RSF1 requires CEBP/ β and hSNF2H to promote IL-1β-mediated angiogenesis: The clinical and therapeutic relevance of RSF1 overexpression and amplification in myxofibrosarcomas. Angiogenesis. 2021 Aug;24(3):533-548 (Corresponding author, SCI 2023 IF=9.2, rank: 3/96=3.1% in Peripheral Vascular Disease)

3. Kung HC, Hsiao YT, Huang HY, Hsiao CC. Infant malignant ectomesenchymoma masquerading as inguinal hernia in two patients. Pediatr Neonatol. 021 May;62(3):324-326. (SCI 2023 IF=2.3, rank: 53/186=28.5% in Pediatrics)

4. Lee JC*, Li WS, Kao YC, Chung YC, Huang HY*. Toward a unifying entity that encompasses most, but perhaps not all, inflammatory leiomyosarcomas and histiocyte-rich rhabdomyoblastic tumors. Mod Pathol 2021 Jul;34(7):1434-1438 (co-corresponding author)(SCI,2023 IF: 7.1, rank: 5/88=5.7 % in Pathology)

5. Chen CF, Peng SL, Lee CC, Lui CC, Huang HY, Chien CY. Dynamic contrast-enhanced magnetic resonance imaging in correlation with tongue cancer stages. Acta Radiol. 2021 Dec;62(12):1618-1624.  (SCI,2023 IF: 1.1, rank: 153/204 =75.0 % in Radiology,Nuclear Medicine &Medical Imaging)

6. Mathai AM, Alexander J, Huang HY, Li CF, Jeng YM, Fung KM, Harris WP, Swanson PE, Truong C, Yeh MM. S100P as a marker for poor survival and advanced stage in gallbladder carcinoma. Ann Diagn Pathol. 2021 Mar 22;52:151736. doi: 10.1016/j.anndiagpath.2021.151736. (SCI,2023 IF: 1.5, rank: 56/88 =63.6% in Pathology)

7. Chen PC, Huang HY, Chung MY, Pan CC. Ossifying low grade endometrial stromal sarcoma with PHF1-BRD8 fusion. Cancer Genet. 2021 Apr 22;256-257:81-85. (SCI,2023 IF: 1.4, rank: 152/191=79.6% in Genetics & Heredity) 

8. Kao YC, PH Lee, Wu CL, Yu SC, Huang HY*. Superficial ALK-rearranged myxoid spindle cell neoplasm with a novel FMR1-ALK fusion gene. Mod Pathol. 2021 Mar;35(3):438-441 (corresponding author,2023 IF: 7.1, rank: 5/88 =5.7 % in Pathology).

9. Chen CH, Chang KC, Chuang CH, Huang HY*. The emerging PRRX1-NCOA fibroblastic neoplasm: A combined reappraisal of published tumors and two new cases. Virchows Arch. 2021 (corresponding author, SCI,2023 IF:3.4, rank, 22/88=25.0% in Pathology)

10. Liang CW, Fang PW, Huang HY, Lo CM. Deep convolutional neural networks detect tumor genotype from pathological tissue images in gastrointestinal stromal tumors. Cancers 2021 in press (SCI, 2023 IF:4.5, rank, 78/322=24.2% in oncology).

11. Lee PH, Kao YC, Hsieh TH, Liao JB, Li CF, Lee JC, Chang YM, Chang CD, Huang SC, Chen TZ, Liu TT, Yu SC, Huang HY*. Myoepithelial and oral intracranial myxoid mesenchymal tumor-like neoplasms as diagnostic considerations of the ever-expanding extracranial myxocollagenous tumors harboring FET-CREB fusions. Pathol Res Pract 2021, Nov in press (corresponding author, (SCI,2023 IF:2.9, rank, 28/88=31.8% in Pathology)

12. Lee PH^#, Huang SC^#, Wu PS^{^}, Tai HC^{^}, Lee CH, Lee JC, Kao YC, Tsai JW, Hsieh TH, Li CF, Li WS, Liu TT, Su YL, Yu SC, Huang HY*. Molecular characterization of dermatofibrosarcoma protuberans: the clinicopathologic significance of uncommon fusion gene rearrangements and their diagnostic importance in the exclusively subcutaneous and circumscribed lesions. Am J Surg Pathol. 2022 Jul 1;46(7):942-955. (Corresponding author,( SCI,2023 IF:4.5, rank, 19/290=6.6 % in Surgery)

13. Tsai JW^§, Lee JC^§, Hsieh TH, Huang SC, Lee PH, Liu TT, Kao YC, Chang CD, Weng TF, Li CF, Lin JC, Liang CW, Su YL, Chang IYF, Wang YT, Chang NY, Yu SC, Wang JC, Huang HY*. Adult NTRK-rearranged spindle cell neoplasms of the viscera: with an emphasis on rare locations and heterologous elements. Mod Pathol. 2022 July; (35):911–921. (Corresponding author,SCI,2023 IF: 7.1, rank: 5/88 =5.7 % in Pathology).

14. Kuo CT, Kao YC, Huang HY, Hsiao CH, Lee JC. Malignant gastrointestinal neuroectodermal tumor in head and neck: two challenging cases with diverse morphology and different considerations for differential diagnosis. Virchows Arch. 2022 Jan 18. doi: 10.1007/s00428-022-03274-y. (SCI,2023 IF:3.4, rank, 22/88=25.0% in Pathology)

15. Kao YC, Kuo CT, Kuo PY, Huang HY, Lu TP, Hsieh TH, Fletcher CDM, Lee JC. Pulmonary "Inflammatory Leiomyosarcomas" Are Indolent Tumors With Diploid Genomes and No Convincing Rhabdomyoblastic Differentiation. Am J Surg Pathol. 2022 Mar 1;46(3):424-433. (Corresponding author, SCI,2023 IF:4.5, rank, 19/290=6.6 % in Surgery)

16. Liu TT, Chien-Feng Li CF, Tan KT, Jan YH, Lee PH, Huang CH, Yu SC, Tsao CF, Wang JC, Huang HY* Characterization of aberrations in DNA damage repair pathways in gastrointestinal stromal tumors: the clinicopathologic relevance of γH2AX and 53BP1 in correlation with heterozygous deletions of CHEK2, BRCA2, and RB1. Cancers (Basel). 2022 Mar 31;14(7):1787. doi: 10.3390/cancers14071787. (SCI, 2023 IF:4.5, rank, 78/222=24.2% in oncology).

17. Chen CC, Wu PH, Chuang SC, Huang HY. Sublingual clear cell carcinoma with liver metastasis: A case report and literature review. Kaohsiung J Med Sci. 2022 Jun 15. doi: 10.1002/kjm2.12567. (SCI, 2023 IF:2.7, rank, 95/189=50.3% in Medicine, General & Internal).

18.  Chen KH, Huang HY, Chen TC, Liu YJ, Lin IC, Ng KF, Chuang HC, Huang SC. A clinicopathological reappraisal of orbital vascular malformations and distinctive GJA4 mutation in cavernous venous malformations. Hum Pathol. 2022 Oct 6:S0046-8177(22)00241-6. doi: 10.1016/j.humpath.2022.10.002. (SCI, 2023 IF:2.7, rank, 31/88=35.2% in Pathology).

19. Chang Chien YC, Madarász K, Csoma SL, Mótyán JA, Huang HY, Méhes G, Mokánszki A. Molecular Identification and In Silico Protein Analysis of a Novel BCOR-CLGN Gene Fusion in Intrathoracic BCOR-Rearranged Sarcoma. Cancers (Basel). 2023 Jan 31;15(3):898. (SCI, 2023 IF:4.5, rank, 78/322=24.2% in Oncology).

20. Huang SC, Chang IYF, Chang CJ, Liu H, Chen KH, Liu TT, Hsieh TY, Chuang HC, Chien-Cheng Chen, Lin IC, Ng KF, Huang HY*, Chen TC*. Association between hepatic angiosarcoma and end-stage renal disease: nationwide population-based evidence and enriched mutational signature of aristolochic acid exposure. J Pathol. 2023 June;260(2):165–176 (co-corresponding authors, SCI in press, (SCI, 2023 IF:5.6, rank, 8/88=9.1% in Pathology).

21. Kao YC, Yoshida A, Hsieh TH, Nord KH, Saba KH, Ichikawa H, Tsai JW, Huang HY, Chih-Hsueh Chen P, Fletcher CDM, Lee JC. Identification of COL1A1/2 Mutations and Fusions With Noncoding RNA Genes in Bizarre Parosteal Osteochondromatous Proliferation (Nora Lesion). Mod Pathol. 2023 Feb;36(2):100011 (SCI, 2023 IF: 7.1, rank: 5/88 =5.7 % in Pathology).

22. Huang SC, Lee JC, Hsu YC, Tsai JW, Kao YC, Hsieh TH, Chang YM, Chang KC, Wu PS, PCH, Chen CH, Chang CD, Lee PH, Tai HC, Liu TT, Wen MC, Li WS, Yu SC, Wang JC, Huang HY*. Extraskeletal myxoid chondrosarcomas: the uncommon clinicopathologic manifestations and significance of TAF15::NR4A3 fusion in 58 molecularly confirmed cases. Mod Pathol. 2023 Jul;36(7):100161. (Corresponding author, SCI, 2023 IF: 7.1, rank: 5/88 =5.7 % in Pathology).

23. Li CF, Chan TC, Fang FM, Yu SC, Huang HY.* PAK1 overexpression promotes myxofibrosarcoma angiogenesis through STAT5B-mediated CSF2 transactivation: clinical and therapeutic relevance of amplification and nuclear entry. Int J Biol Sci. 2023 Jul 31;19(12):3920-3936. (Corresponding author,SCI, 2023 IF:8.2, rank: 31/313 =9.9 % in
Biochemistry & Molecular Biology).

24. Lee JC, Hsieh TH, Kao YC, Tsai CF, Huang HY, Shih CY, Song HL, Oda Y, Chen PC, Pan CC, Sittampalam K, Petersson F, Konishi E, Chiu WY, Chen CF, Carpenter TO, Lu TP, Chang CD, Huang SC, Folpe AL. Klotho overexpression is frequently associated with upstream rearrangements in fusion-negative phosphaturic mesenchymal tumors of bone and sinonasal tract. Mod Pathol. 2023 Sep 22:100336. doi:10.1016/j.modpat.2023.100336.( SCI, 2023 IF: 7.1, rank: 5/88 =5.7 % in Pathology.)

25. Koshyk O, Dehner CA, van den Hout MFCM, Vanden Bempt I, Sciot R, Huang HY, Agaimy A, Din NU, Klubí?ková N, Mosaieby E, Skálová A, Michalová K, Sch?ffski P, Oliveira AM, Halling KC, Gupta S, Gross JM, Nin JWM, Michal M, Folpe AL, Kosemehmetoglu K, Torres-Mora J, Michal M. EWSR1::POU2AF3(COLCA2) Sarcoma: An aggressive, polyphenotypic sarcoma with a head and neck predilection. Mod Pathol. 2023 Sep 22:100337. doi: 10.1016/j.modpat.2023.100337. (SCI, 2023 IF:7.1, rank: 5/88 =5.7 % in Pathology.)

26. Wang SH, Huang HY, Medeiros LJ, Chang KC. ALK-positive histiocytosis of external auditory canal in a 3-year-old boy. Am J Hematol. 2023 Oct 26. doi: 10.1002/ajh.27143. Online ahead of print. (SCI, 2023 IF: 10.1, rank: 8/97 =8.2 % in Hematology.)

27. Huang HY, Lo CM, Lu HI, Chang JP. Huge ancient schwannoma causing acute respiratory failure: a case report. J Cardiothorac Surg. 2024 Mar 15;19(1):131. (SCI, 2023 IF: 1.5, rank: 153/290 =52.8 % in Surgery.) 

28. Lee JC^#, Lee PH^#, Li SC^{^,}, Liao KC^{^}, Chang YM, Chen HC, Kao YC, Wu PS, Huang SC, Tsai JW, Hu CF, Li CH, Liu TT, Yu SC, Wang JC, Huang HY^*. Systematic characterization of the clinical and pathological features of schwannomas harboring SH3PXD2A::HTRA1 fusion. Mod Pathol. 2024 Mar;37(3):100427. (Corresponding author, (SCI, 2023 IF: 7.1, rank: 5/88 =5.7 % in Pathology;) #, co-first authors, ^, equal contribution).

29. Lee PH, Huang SC, Lee JC, Li SC, JTsai JW, Chang YM, Kao YC, Wen-Lang Fan WL, Chang CD, Chen HC, Li CH, Hu CF, Liu TT, Wu PS, Nam MH, Yu SC, Wang JC, Huang HY^*. In-frame insertions of SOX10 are highly enriched and characterize a distinct transcriptomic profile in gastrointestinal schwannomas. J Pathol. 2025 March. (Corresponding author, SCI in press, (SCI, 2023 IF:5.6, rank, 8/88=9.1% in Pathology).

30. Huang SN, Kao YC, Lee JC, Huang HY, Chang C, Li WS, Hsieh TH, Nam MH. Pseudomyogenic hemangioendothelioma: A series of 13 patients, highlighting unusual cardiac locations, novel gene fusions, and malignant behavior. Pathol Res Pract. 2025 Nov;275:156254. (SCI, 2024 IF: 3.2, rank: 24/90 =5.7 % in Pathology)

31. Chou CC, Lee JC, Wu PS, Kao YC, Chang YM, Huang SC, Hsu YC, Pan CC, Hang JF, Liang PI, Tsai JW, Lee PH, Li CH, Hu CF, Yu SC, Huang HY. Genitourinary Mesenchymal Neoplasms with Tumor-Defining Genetic Alterations: A Clinicopathologic and Molecular Correlative Study of 71 cases. Hum Pathol. 2025 Oct 21:105953. (corresponding author, SCI in press, 2024 IF:2.6, rank, 35/90=38.9% in Pathology).

32. Lee CH, Lee YS, Bennett JA, Kolin DL, Lee JC, Huang HY, K?bel M, Sementsov M, Dickson BC, Koelsche C, Kommoss F, von Deimling A, Kommoss FKF. GREB1-rearranged uterine tumour shares a common DNA methylation signature with ESR1-rearranged UTROSCT. Histopathology. 2026 Apr;88(5):1084-1093. (SCI 2025 IF: 3.8, rank: 19/90 =21.1 % in Pathology)

33. Hu CF, Huang HY, Li WS, Lee CH. Primary pulmonary composite hemangioendothelioma harboring a YAP1::FOXR1 fusion. Pathology (SCI in press, 2025 IF: 3.9, rank: 17/90 =18.9 % in Pathology)

Awards and Honors

2014  Bronze Award, National Biotechnology and Medical Care Quality Award:
Deciphering Complex and Rare Tumor Groups: Pioneering Connective Tissue Pathology

2010  Taiwan Society of Pathology–Yeh Shu Foundation Best Paper Award

2009  Ta-You Wu Memorial Award, National Science Council, Executive Yuan